Argent BioPharma Limited
Research Argent BioPharma Limited (H5O0) on Bullrun: market cap EUR 1.63M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerH5O0
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 1.63M
- Financial periodFY2025
- RevenueAUD 583.45K
- Revenue growth-34.5%
- Net income-AUD 17.84M
- Free cash flow-AUD 9.28M
- Gross margin76.5%
Valuation Snapshot
latest market cap is EUR 1.63M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 583.45K | -AUD 17.84M | -AUD 9.28M | 76.5% | -0.31 | AUD 1.02M | AUD 8.29M | -AUD 8.63M |
| FY2024 | AUD 891.08K | -AUD 17.53M | -AUD 14.40M | 22.9% | -0.47 | AUD 702.87K | AUD 1.04M | -AUD 5.15M |
| FY2023 | AUD 3.39M | -AUD 20.82M | -AUD 11.26M | 42.8% | -7.1 | AUD 239.82K | AUD 575.14K | -AUD 7.51M |
| FY2022 | AUD 4.73M | -AUD 16.77M | -AUD 14.85M | 38.2% | -6.5 | AUD 1.79M | AUD 4.39M | AUD 11.23M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 1.63M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Argent BioPharma Limited
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Argent BioPharma Limited's market cap?
Argent BioPharma Limited's market capitalization is EUR 1.63M.
What does Argent BioPharma Limited do?
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's.